Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110336 | PMC |
| http://dx.doi.org/10.3389/fpsyg.2020.00426 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gynecological cancers: Bridging the gap between research and cure.
Eur J Surg Oncol
January 2025
Dipartimento di Scienze Chirurgiche, University of Turin, Italy.
Approximately 1.5 million women suffer from gynecological malignancies every year. Around 60 % of these cancers are classified as rare in the European population.
View Article and Find Full Text PDFAdvancing neurocritical care: Bridging molecular mechanisms and physiological monitoring to neurotherapeutics.
Neurotherapeutics
January 2025
Division of Neuroscience Critical Care, Departments of Neurology, Anesthesiology and Critical Care Medicine, and Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address:
Bridging the gap: tackling the challenge of limited progressors in clinical trials aimed at slowing the transition from early preradiographic to established osteoarthritis.
Ann Rheum Dis
January 2025
International Drug Development Institute, Louvain-la-Neuve, Belgium; I-BioStat, Hasselt University, Hasselt, Belgium.
Interrupted versus uninterrupted anticoagulation for cardiac rhythm management device insertion.
Cochrane Database Syst Rev
January 2025
Department of Pharmacy Practice, University of Connecticut, Storrs, CT 06269, USA.
Background: Guideline-recommended strategies to interrupt chronic anticoagulation with warfarin or direct oral anticoagulants (DOAC) during the perioperative period of cardiac implantable electronic device (CIED) surgery differ worldwide. There is uncertainty concerning the benefits and harms of interrupted and uninterrupted anticoagulation in patients undergoing CIED surgery.
Objectives: To assess the benefits and harms of interrupted anticoagulation (IAC) with either warfarin or DOAC in the perioperative period of CIED surgery versus uninterrupted anticoagulation (UAC), with or without heparin bridging, during an equivalent time frame, for CIED surgery.
Glucose-6-phosphate dehydrogenase regulates mitophagy by maintaining PINK1 stability.
Life Metab
February 2025
Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117593, Singapore.
Glucose-6-phosphate dehydrogenase (G6PD) is the rate-limiting enzyme in the pentose phosphate pathway (PPP) in glycolysis. Glucose metabolism is closely implicated in the regulation of mitophagy, a selective form of autophagy for the degradation of damaged mitochondria. The PPP and its key enzymes such as G6PD possess important metabolic functions, including biosynthesis and maintenance of intracellular redox balance, while their implication in mitophagy is largely unknown.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!